Fri, Dec 26, 2014, 7:21 AM EST - U.S. Markets open in 2 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

wisemanrax 13 posts  |  Last Activity: Dec 22, 2014 8:34 PM Member since: Oct 14, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • wisemanrax wisemanrax Dec 22, 2014 8:34 PM Flag

    There is a lot of attention to JUNO because CAR therapies have yet to be proven effective/ineffective and hence everyone being excited about it. With NWBO, we have another company that is developing Dendritic based cell vaccines but is shrouded due to negative press from bloggers and the association with DNDN because the mindset of most people who glance at this think "Well it didn't work for DNDN, that means it won't work for NWBO".

  • Reply to

    DCVax Direct - The Numbers

    by hope4patients Dec 18, 2014 12:54 PM
    wisemanrax wisemanrax Dec 18, 2014 5:33 PM Flag

    Potential is there for almost every new cell based therapy but for now, the closest measure we have is the GBM phase III trial which should be wrapping up on September 2015.

  • Reply to

    DCVax Direct - The Numbers

    by hope4patients Dec 18, 2014 12:54 PM
    wisemanrax wisemanrax Dec 18, 2014 5:06 PM Flag

    I was specifically talking about DCVax L phase III trial which has a placebo cohort and in that case for those patient it is surgery, radiation, and autologous PBMC ( with a choice for patient to choose DCVax if there is progression ). Look at the clinical trials wbesite if you don't believe me.

  • Reply to

    DCVax Direct - The Numbers

    by hope4patients Dec 18, 2014 12:54 PM
    wisemanrax wisemanrax Dec 18, 2014 4:44 PM Flag

    Straight from the clinicaltrials.gov site:

    The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and Temodar therapy and two out of three will additionally receive DCVax-L, with the remaining one third receiving a placebo. Patients randomized to the placebo arm will have the option to receive DCVax-L in a crossover arm upon documented disease progression. (note: DCVax-L when used for patients with brain cancer is sometimes also referred to as DCVax-Brain

    There is a placebo which is just autologous PBMC but the patients do have an option to get the treatment after progression. You always have to have a control for any clinical trial.

  • Reply to

    DCVax Direct - The Numbers

    by hope4patients Dec 18, 2014 12:54 PM
    wisemanrax wisemanrax Dec 18, 2014 4:01 PM Flag

    I believe Amgen has 13 products out in the market with a value of 165/share as you say. NWBO has nothing out yet and I don't think NWBO will get to $1000 even with 5 years in....assuming every clinical trial result for all types of cancer indications leads to a great improvement in both PFS and OS in comparison with placebo. Doing that ratio comparison is ridiculous as well since you do not know whether they will raise more money to continue operations if they go at it alone.

  • Reply to

    DCVax Direct - The Numbers

    by hope4patients Dec 18, 2014 12:54 PM
    wisemanrax wisemanrax Dec 18, 2014 2:48 PM Flag

    $1000 per share!?!?! C'mon dude, that is ridiculous. Where do you get $80,000 from anyway?

  • Reply to

    Juno IPO

    by momentum2play Dec 17, 2014 10:45 AM
    wisemanrax wisemanrax Dec 17, 2014 1:18 PM Flag

    I'm sorry the book costs $80 and there is actually a kindle edition as well.

  • Reply to

    Juno IPO

    by momentum2play Dec 17, 2014 10:45 AM
    wisemanrax wisemanrax Dec 17, 2014 1:15 PM Flag

    If you really want to understand the science behind these kinds of therapies, get the book Janeway's Immunobiology 8th edition. It will give you the fundamentals to understand the players in your immune system. It should be like $30 on Amazon right now or go to a university library and see if you can borrow it.

  • Reply to

    Juno IPO

    by momentum2play Dec 17, 2014 10:45 AM
    wisemanrax wisemanrax Dec 17, 2014 12:58 PM Flag

    It's not really Dendreon reborn, just a different strategy to cell therapy. Juno's form of cell therapy will actually infuse the modified T-cells which are the effectors that are going to be doing the actual killing kind of like what Bluebird Bio is trying to do in their cooperation with Celgene. With Dendreon, Immunocellular Therapeutics, and Northwest Biotherapeutics the strategy is to get the dendritic cells in the patient to teach the T-cells what to kill. '
    So with lets say Immunocellular Therapeutics they are going to load a bunch of antigens into the dendritic cells in the lab, make sure they present those antigens, and then actually teach the patient's immune system to kill. Northwest's strategy for GBM is to make this cell therapy a bit more personalized since they make sure that the dendritic cells will display anything that was found in the tumor lysate and it is unique to each individual.

  • Reply to

    Why no buyout from big pharma right now?

    by benji2vvv Dec 16, 2014 11:10 AM
    wisemanrax wisemanrax Dec 16, 2014 12:15 PM Flag

    I never said there was too much risk, but risk as with any small molecule and biologic out there in clinical trials. We dont know if an offer has been made and my suggestion that a low offer was made was pure speculation, just like your belief that an offer hasn't been made at all.

  • Reply to

    Why no buyout from big pharma right now?

    by benji2vvv Dec 16, 2014 11:10 AM
    wisemanrax wisemanrax Dec 16, 2014 11:24 AM Flag

    Meant to say big pharma

  • Reply to

    Why no buyout from big pharma right now?

    by benji2vvv Dec 16, 2014 11:10 AM
    wisemanrax wisemanrax Dec 16, 2014 11:23 AM Flag

    Maybe they did make an offer but it was too low. You also have to remember that they have not finished phase 3 for the GBM indication and while the case studies are encouraging, it would make sense for big pharmacy to wait for FDA approval in order to take the risk off.

  • Reply to

    Is Turing Pharmaceuticals Martin's new company?

    by wolleyrobin Oct 14, 2014 8:35 AM
    wisemanrax wisemanrax Oct 14, 2014 4:09 PM Flag

    .turingpharmadotcom/ replace the dot with an actual . It just shows the title of the company once you reach that webpage. Also, MS is the new CEO and yopu can search for the company on LinkedIn just as mkerryfuller said.

    Sentiment: Hold

OPTR
12.780.0000(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Avis Budget Group, Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 12:59 PM EST